Beta-adrenergic blockers are increasingly used in the treatment of angina pectoris (Hamer et al., 1964 Srivastava, Dewar, and Newell, 1964; Gillam and Prichard, 1965, 1966; Keelan, 1965; Rabkin et al., 1966; Wolfson et al., 1966) , cardiac arrhythmias (Stock and Dale, 1963; Ginn, Irons, and Orgain, 1965; Harrison, Griffin, and Fiene, 1965; Bath, 1966; Harris, 1966; Rowlands, Howitt, and Markman, 1965; Schamroth, 1966; Szekely et al., 1966) , and some other less common conditions (Harrison et al., 1964) . The danger of inducing or aggravating heart failure by beta-blockade remains a matter of controversy (Stephen, 1966) . Whereas this risk has been considered as relatively small and acceptable by Snow (1965 Snow ( , 1966 , undesirable side-effects and sometimes severe complications related to the depressant action of propranolol on myocardial contractility have been reported, in isolated instances with fatal outcome (Fleckenstein et al., 1964; Vogel, 1965; Scheu, 1966; Luthy and Hegglin, 1966) . This risk undoubtedly represents an important drawback to this kind of therapy.
severity of the heart disease. CIBA 39,089-Ba has a negative chronotropic effect fairly similar to that of propranolol, but produces a significantly less marked depression of myocardial contractility. 
PATIENTS AND METHODS
Studies were made on 12 patients with propranolol (Group I) and on 22 patients with CIBA 39,089-Ba (Group II). Tables I and II sum up the clinical data of these patients. The study includes 8 patients with aortic stenosis, 7 with aortic incompetence, 3 with mixed aortic valve disease, 9 with moderate to severe mitral incompetence, 4 with mixed aortic and mitral valve disease (excluding mitral stenosis), 2 with mild primary myocardial disease, and 1 with ventricular septal defect.
Electrocardiographic evidence of left ventricular hypertrophy was shown by 24 patients and tracings indicating "left ventricular strain" were noted in another 24. In Group I, 5 patients and in Group II, 17 patients were or had previously been in overt heart failure and were digitalized at the time of the study. In all of them, the diagnosis was confirmed by left heart catheterization and angiocardiography, as well as in 16 patients by open-heart surgery.
Right heart catheterization was used, as this was thought more suitable for long-lasting studies with repeated exercise tests. A double-lumen Cournand catheter was wedged into the pulmonary capillary position, and a cannula was inserted into the brachial artery. propranolol and from 78 to 66 beats/min. (-15%) exercise is not statistically significant. Both drugs after CIBA 39,089-Ba. During exercise, it was reduced the resting cardiac output. After propradecreased from 107 to 97 beats/min. (-9%) after nolol, there was no adjustment of the stroke volume propranolol, and from 14 to 96 beats/min. (-16%) to the lower heart rate, and cardiac output fell in after CIBA 39,089-Ba. The greater fall in heart direct proportion to the fall in heart rate, i.e. from rate noticed in response to CIBA 39,089-Ba during 5-1 to 4-4 1./min. (-15% Effects of Beta-adrenergic Blockade in Organic Heart Disease reduction in the cardiac output from 9 1 to 8'2 1./mn.
At rest, there was no change in the arterial pressure after propranolol and a 7 per cent increase after CIBA 39,089-Ba. With respect to the lower cardiac output, this means a 17 per cent increase in total peripheral vascular resistance after propranolol and a 9 per cent increase after CIBA 39,089-Ba. During exercise, neither drug affected the total peripheral vascular resistance, both arterial pressure and cardiac output having been reduced to a similar extent by both beta-blockers.
There was a difference in the effects of the two drugs on the pulmonary wedge pressure (Fig. 4) during exercise. At rest, there was a good correlation between this effect and the severity of the underlying heart disease. The increase was slight in mildly diseased, well-compensated subjects with normal resting pulmonary capillary pressure, but was conspicuous in 4 patients (Case 3, + 11 mm. Hg; Case 6, +12 mm. Hg; Case 7, +4 mm. Hg; and Case 10, + 7 mm. Hg). These four patients were or had previously been in frank heart failure and were digitalized at the time of this investigation. During exercise, the pulmonary capillary pressure was increased by propranolol in all subjects, irrespective of the presence or absence of heart decompensation.
After CIBA 39,089-Ba, a single patient (Case 30) showed an increase of 8 mm. Hg in his resting pulmonary wedge pressure from 14 to 22 mm. Hg. This patient died 3 months after the study from intractable heart failure. Necropsy showed a maximally damaged heart weighing over 900 g. In all the other patients in this group, the drug produced only minor changes, with an average decrease of 1 mm. Hg from 13 to 12 mm. Hg at rest, and from 25 to 24 mm. Hg during exercise. This difference in the effects of the two drugs on the resting and exercising pulmonary wedge pressure is highly significant (p < 0 001).
In this regard, it is of interest to analyse separately the effects of the two beta-blockers in patients with severe, pure mitral incompetence (Fig. 5-7) . In 3 such patients (Cases 26-28 in Table II) , CIBA 39,089-Ba decreased the resting pulmonary capillary pressure on an average by 5 mm. Hg from 23 to 18 mm. Hg, by reducing the frequency and the height of the V waves, suggesting decreased mitral regurgitation, and also by lowering the levels of the Y dips, indicating decreased left ventricular diastolic pressures (Fig. 6) . In 3 similar patients (Cases 6, 7, and 10 in Table I duced an opposite effect. Despite full digitalization in all 3, the drug increased the resting pulmonary wedge pressure by 7 mm. Hg from 20 to 27 mm. Hg, with a rise in the height of the V waves and in the levels of the Y dips (Fig. 7) . DISCUSSION Effects of Propranolol. The slowing effect of this drug on the heart rate at rest and during exercise is well known and does not require further comment. A significant reduction in cardiac output after propranolol is a constant finding in man, both in health and in heart disease (Hamer and Sowton, 1965; Sowton and Hamer, 1966; Paley, McDonald, and Peters, 1965; Robinson et al., 1965; Harris et al., 1966) , and in animals (Black and Rolett, 1965; Nakano and Kusakari, 1965 (Table II) . Before injection of the drug, prominent V waves reaching 30 to 35 mm. Hg and a mean pulmonary wedge pressure of 22 mm. Hg were recorded; in spite of maximal digitalization, there was a poorly controlled ventricular rate of over 120/min.
Below: the drug produced a dramatic fall in heart rate down to 60-65/min., a decrease in the height of the V waves, and a drop in the mean pulmonary wedge pressure down to 14 mm. Hg. In spite of the smaller V waves, the forward stroke output was increased from 23 to 38 ml./systole, thereby offsetting to a large extent the effect of bradycardia. The tip of the catheter was not displaced between the two readings.
(1966), who found no changes in stroke output after propranolol, and therefore a directly proportional decrease in cardiac rate and output. The mechanism underlying this reduction is not entirely clear. Both increased and decreased heart sizes have been observed in response to beta-adrenergic blockade. An increase in systolic and diastolic heart size following treatment with beta-blockers has been ascribed both to longer diastolic filling period due to the lowered heart rate and to impaired myocardial contractility (Chamberlain, 1966) . Decreased systolic and diastolic heart volumes after propranolol have been related to a possible nitroglycerinlike venous pooling and to impaired venous return (Wolfson et al., 1966) . In the present study, changes in heart volumes following beta-blockade have nxot been measured. Yet, in spite of the lower heart rate, no significant change in right ventricular filling pressure was found after propranolol, which may account for the unchanged stroke output. In addition, it must be stressed that no correlation became evident between the amount of fall in cardiac output and the severity of the underlying heart disease. This suggests that the depressant effect of propranolol on myocardial contractility plays only a minor role in its effect on resting cardiac output, at least in healthy subjects and in wellcompensated heart patients. The effect of propranolol on the pulmonary capillary pressure is of interest. After propranolol the left ventricle produced an unchanged stroke work, at least in cases without aortic obstruction, but probably at the expense of some rise in its filling pressure, since the pulmonary wedge pressure was increased by 4 mm. Hg at rest and by 7 mm. Hg during exercise (which probably reflects a similar increase in the left ventricular telediastolic pressure). This effect was minimal in mildly diseased patients without heart failure, but was clearly evident in the more severely ill patients. It also became obvious in all subjects during exercise. These findings are somewhat similar to those Table I . After the drug, there was an increase in the height of the V waves and in the mean pulmonary wedge pressure. At rest (above), this pressure was increased by 7 mm.
Hg, and during exercise (below), by 12 mm. Hg by the drug.
noticed in patients with ischaemic heart disease . They are even more significant in view of the fact that pulmonary artery and capillary pressures are expected to be lower during the second of two identical periods of exercise a short time apart (Widimsky, Berglund, and Malmberg, 1963; Burkart, Barold, and Sowton, 1967) . Hence, it must be concluded that propranolol depresses myocardial contractility to some extent and may aggravate cardiac decompensation in patients with latent or overt heart failure. The four patients whose resting pulmonary wedge pressure was much increased in response to propranolol were fully digitalized at the time of the study. Thus, digitalization may sometimes fail to protect decompensated patients against a deleterious effect of propranolol on myocardial function.
No unpleasant subjective side-effects were produced by propranolol nor did any patient become aware of the changes in haemodynamic conditions induced by the drug.
Effects of CIBA 39,089-Ba. The reduction in heart rate following treatment with CIBA 39,089-Ba was closely similar to that produced by the same dose of propranolol. Therefore, CIBA 39,089-Ba and propranolol may be considered as practically equipotent beta-adrenergic inhibitors in terms of their negative chronotropic effects. Yet, the two drugs differed significantly as regards their effect on the resting cardiac output. Whereas after propranolol there was no adjustment of the stroke output to the lowered heart rate, the reduction in heart rate following injection of CIBA 39,089-Ba was almost entirely offset by a 10 per cent increase in stroke output, thus resulting in a mere 3 per cent decrease in cardiac output. During exercise, the same effect was observed in response to CIBA 39,089-Ba, but the increase in stroke volume was small and hence incapable of compensating for the fall in heart rate.
There was a highly significant difference in the effects of the two drugs on the pulmonary wedge pressure. Propranolol produced a rise in this pressure, but no such change occurred after CIBA 39,089-Ba. After this latter drug, the 10 per cent increase in left ventricular stroke work in response to the lowered heart rate was apparently achieved without there being any rise in left ventricular filling pressure. With the exception of Case 30, already discussed, comparable findings were obtained after CIBA 39,089-Ba in all subjects of Group II, irrespective of the presence or absence of heart failure. These data suggest that, in most instances, this drug does not depress myocardial contractility to the same extent as does propranolol.
Since propranolol sometimes produced an alarming rise in pulmonary wedge pressure in patients with heart failure, despite full digitalization, such patients were excluded from further experimentation with this drug. This restriction did not apply to CIBA 39,089-Ba, since this latter drug did not affect the pressures in the lesser circulation. Consequently, Group II (patients studied with CIBA 39,089-Ba) included on an average more severely ill patients than those in Group I. This difference was evident from the exercising pulmonary capillary pressure, which was 19 mm. Hg in Group I and 25 mm. Hg in Group II. Yet, this difference favours propranolol and tends to enhance the difference in the effects of the two beta-blockers on myocardial contractility.
The mechanism underlying this difference is not evident. Brunner et al. (1967) , working with catecholamine-depleted cats, noticed a positive inotropic effect of CIBA 39,089-Ba. This suggests that this drug has-some intrinsic sympathomimetic action which, at the doses used in the present study, may remain effective as regards the inotropic function of the myocardium, while it is overcome by the beta-blocking properties of the drug as regards the chronotropic functions of the heart. Recently, Levy and Richards (1966) , comparing the inotropic and chronotropic effects of 6 beta-adrenergic blocking drugs and of their optical isomers*, showed that some of these compounds (dl-K6-592 and dl-propranolol), while having almost equipotent betaadrenolytic properties, differed widely with respect to their inotropic effects on the heart. They found that pronethalol and propranolol had an intrinsic depressant effect on myocardial contractile force unrelated to their beta-adrenergic blocking potency, possibly connected with their chemical structures, i.e. with the naphthyl-nucleus characteristic of these two drugs. In view of these findings, the * Pronethalol, propranolol, dichloroisoproterenol, MJ-1998 , MJ-1999 The data presented suggest that CIBA 39,089-Ba acts as a potent beta-adrenergic receptor inhibitor in terms of its effects on the regulation of the heart rate, but differs from propranolol in that it depresses myocardial contractility to a significantly less pronounced extent. If confirmed in further experimentation, this evidence would have important therapeutic implications, since with CIBA 39,089-Ba, full benefit of beta-adrenergic blockade may be given to patients at a definitively lower risk of aggravating heart failure. Up to the present, over 50 patients have been treated in this hospital with this drug with satisfactory results and no detectable side-effects. The compound is regularly effective by the oral route, and seems to represent an appreciable advance in the therapeutic scope of beta-adrenergic blocking drugs.
SuMMARY
In order to evaluate the risk of precipitating heart failure with beta-adrenergic blocking drugs, 34 patients with organic disease of the left heart were given either 5 mg. propranolol or 5 mg. CIBA 39,089-Ba, a new specific beta-receptor antagonizer, during the course of pre-operative catheterization. Propranolol slowed the heart rate by 16 per cent at rest and by 9 per cent during exercise, and reduced the cardiac output by 15 per cent at rest and by 17 per cent during exercise. While the left ventricular stroke work remained practically unchanged, there was a 4 mm. Hg increase in pulmonary wedge pressure at rest and a 7 mm. Hg increase during exercise following treatment with propranolol. This finding is considered as evidence of a depressant effect of the drug on myocardial contractility. This effect was slight in well-compensated patients, but was considerable in patients with increased resting pulmonary wedge pressure.
CIBA 39,089-Ba produced an effect very similar to that of propranolol as regards heart rate, which was lowered by 15 per cent at rest and by 16 per cent during exercise, but produced only a small decrease in the resting cardiac output, the druginduced bradycardia being to a large extent offset by a higher stroke output. Furthermore, this drug did not significantly change the resting or exercising pulmonary wedge pressure even in severely disabled patients in frank heart failure. It is concluded that CIBA 39,089-Ba is a potent beta-receptor blocker in terms of its negative chronotropic effect, but differs from propranolol in that it produces a significantly less conspicuous decrease in myocardial 58 group.bmj.com on November 8, 2017 -Published by http://heart.bmj.com/ Downloaded from
